Purchasing a pipeline – perils, pitfalls, and priorities in asset acquisition
Checkpoint inhibitors. Genetic therapies. Biomarker therapies. To hear big pharma tell it, we are living in an age of medical wonders.
The problem? In some patients, they make a huge difference. In others, they don’t work at all.
From a bench-science standpoint, that’s fascinating. But if you’re a pharmaceutical executive thinking seriously about pipeline asset acquisition, translating large-molecule science into high-profit marketability is fraught with complexity.
In this White Paper, we will look at new and changing trends in pipeline acquisition, discuss difficulties inherent in the current marketplace, and offer worthwhile perspectives on pitfalls and opportunities based on our experience offering strategic guidance to pharmaceutical companies on a global scale.
Big pharma pipelines are not what they used to be
The majority of new drugs measure their success in increments.
Orphan drugs and tightly targeted MOAs offer the most exciting breakthroughs, but they offer them to smaller and smaller groups of patients. New cancer drugs are launched with great fanfare even when their pivotal studies suggest they offer a scant three months’ improvement over the competition. Small molecules are languishing. Biologics, once heralded as an arena of unbounded promise, are nearing the end of their patent lives, negotiating payments worth millions to keep biosimilars off the market.
You may also be interested in…
China Pharma Market Access (CPMA)
Since the establishment of the China National Medical Insurance Bureau in 2018, the goal has been to strengthen public health and medical service levels, achieve maximum utilisation of the national medical insurance fund, and to enhance the strategic purchasing capability of medical insurance funds. Significant tools in achieving this are the National Reimbursement Drug List (NRDL) and drug Volume Based Procurement (VBP), which have opened a new chapter in China’s medical reform. Meanwhile, the new drug registration process is improved, simplified, and accelerated.
George Gu attends DIA meeting in Suzhou
George Gu, Principal and Head of China at Deallus, recently attended the 2023 DIA China Annual Conference where he participated in an expert panel discussion on "Post-Marketing Medical Activities Based on Specialty Drug Pharmacy Management Platform".
Maximise product value through Medical Insights
Medical Insights is emerging as a transformative organisational capability within Medical Affairs that aims to capture real-world insights through medical channels and use them to maximise product and portfolio value.
Deallus sponsoring and speaking at the Pharma CI EU Conference
We are excited to be sponsoring and speaking at the Pharma CI EU conference, held in Rome on 30-31 March 2023. Julie Munch Khan, COO, and Stephen Small, Senior Principal at Deallus will be joining other Competitive Intelligence experts across Pharma, Biotech and Medical Devices.